An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors (original) (raw)

• Adams J, Cuthbert-Heavens D, Bass S, Knowles MA . (2005). Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity. Cancer Lett 220: 137–144.
  Article CAS Google Scholar
• Adler AS, Lin M, Horlings H, Nuyten DS, van de Vijver MJ, Chang HY . (2006). Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet 38: 421–430.
  Article CAS Google Scholar
• Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F et al. (2007). A module of negative feedback regulators defines growth factor signaling. Nat Genet 39: 503–512.
  Article CAS Google Scholar
• Armes JE, Hammet F, de SM, Ciciulla J, Ramus SJ, Soo WK et al. (2004). Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. Oncogene 23: 5697–5702.
  Article CAS Google Scholar
• Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G et al. (2005). Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65: 7591–7595.
  Article CAS Google Scholar
• Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al. (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069–1075.
  Article CAS Google Scholar
• Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N et al. (2008). Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 451: 335–339.
  Article CAS Google Scholar
• Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A . (2003). Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 162: 1807–1815.
  Article CAS Google Scholar
• Garnis C, Lockwood WW, Vucic E, Ge Y, Girard L, Minna JD et al. (2006). High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 118: 1556–1564.
  Article CAS Google Scholar
• Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P et al. (2007). LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807–810.
  Article CAS Google Scholar
• Kendall J, Liu Q, Bakleh A, Krasnitz A, Nguyen KC, Lakshmi B et al. (2007). Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci USA 104: 16663–16668.
  Article CAS Google Scholar
• Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM et al. (2006). Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res 66: 11389–11398.
  Article CAS Google Scholar
• Kwei KA, Kim YH, Girard L, Kao J, Pacyna-Gengelbach M, Salari K et al. (2008). Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 27: 3635–3640.
  Article CAS Google Scholar
• Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY et al. (1999). Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res 59: 5683–5686.
  CAS PubMed Google Scholar
• Lowe SW, Sherri CJ . (2003). Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 13: 77–83.
  Article CAS Google Scholar
• Marks JL, McLellan MD, Zakowski MF, Lash AE, Kasai Y, Broderick S et al. (2007). Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS ONE 2: e426–e426.
  Article Google Scholar
• Matsumoto S, Iwakawa R, Takahashi K, Kohno T, Nakanishi Y, Matsuno Y et al. (2007). Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 26: 5911–5918.
  Article CAS Google Scholar
• Meyerson M, Franklin WA, Kelley MJ . (2004). Molecular classification and molecular genetics of human lung cancers. Semin Oncol 31: 4–19.
  Article CAS Google Scholar
• Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM et al. (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436: 720–724.
  Article CAS Google Scholar
• Mounawar M, Mukeria A, Le CF, Hung RJ, Renard H, Cortot A et al. (2007). Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res 67: 5667–5672.
  Article CAS Google Scholar
• O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500–1508.
  Article CAS Google Scholar
• Ohgaki H, Kleihues P . (2007). Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170: 1445–1453.
  Article CAS Google Scholar
• Owens DM, Keyse SM . (2007). Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26: 3203–3213.
  Article CAS Google Scholar
• Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807–1812.
  Article CAS Google Scholar
• Riely GJ, Kris MG, Rosenbaum D, Marks J, Li AR, Chitale DA et al. (2008). Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14: 5731–5734.
  Article CAS Google Scholar
• Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
  Article CAS Google Scholar
• Sato M, Vaughan MB, Girard L, Peyton M, Lee W, Shames DS et al. (2006). Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 66: 2116–2128.
  Article CAS Google Scholar
• Schulze A, Nicke B, Warne PH, Tomlinson S, Downward J . (2004). The transcriptional response to Raf activation is almost completely dependent on mitogen-activated protein kinase kinase activity and shows a major autocrine component. Mol Biol Cell 15: 3450–3463.
  Article CAS Google Scholar
• Sharma SV, Bell DW, Settleman J, Haber DA . (2007). Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169–181.
  Article CAS Google Scholar
• Shaw AT, Meissner A, Dowdle JA, Crowley D, Magendantz M, Ouyang C et al. (2007). Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev 21: 694–707.
  Article CAS Google Scholar
• Shen WH, Wang J, Wu J, Zhurkin VB, Yin Y . (2006). Mitogen-activated protein kinase phosphatase 2: a novel transcription target of p53 in apoptosis. Cancer Res 66: 6033–6039.
  Article CAS Google Scholar
• Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C et al. (2005). An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 37: 48–55.
  Article CAS Google Scholar
• Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U et al. (2005). Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23: 6829–6837.
  Article CAS Google Scholar
• Tanaka H, Yanagisawa K, Shinjo K, Taguchi A, Maeno K, Tomida S et al. (2007). Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res 67: 6007–6011.
  Article CAS Google Scholar
• The Cancer Genome Atlas Research Network (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061–1068.
  Article Google Scholar
• Tresini M, Lorenzini A, Torres C, Cristofalo VJ . (2007). Modulation of replicative senescence of diploid human cells by nuclear ERK signaling. J Biol Chem 282: 4136–4151.
  Article CAS Google Scholar
• Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R et al. (2007). Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893–898.
  Article CAS Google Scholar
• Zhu CQ, Blackhall FH, Pintilie M, Iyengar P, Liu N, Ho J et al. (2004). Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker. Clin Cancer Res 10: 1984–1991.
  Article CAS Google Scholar